{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:42:10Z","timestamp":1761964930852,"version":"3.40.5"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T00:00:00Z","timestamp":1506297600000},"content-version":"vor","delay-in-days":267,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","respiratorycasereports.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine Case Reports"],"published-print":{"date-parts":[[2017]]},"DOI":"10.1016\/j.rmcr.2017.10.006","type":"journal-article","created":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T21:33:18Z","timestamp":1509053598000},"page":"283-286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Immunotherapy \u201cShock\u201d with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma"],"prefix":"10.1016","volume":"22","author":[{"given":"Paul","family":"Zarogoulidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haidong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodora","family":"Tsiouda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrysa","family":"Sardeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0037-1269","authenticated-orcid":false,"given":"Georgia","family":"Trakada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lemonia","family":"Veletza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasios","family":"Kallianos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoforos","family":"Kosmidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aggeliki","family":"Rapti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liana","family":"Papaemmanouil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Hatzibougias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Drougas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Hohenforst-Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.rmcr.2017.10.006_bib1","doi-asserted-by":"crossref","first-page":"736","DOI":"10.7150\/jca.7734","article-title":"Molecular targeted drugs and biomarkers in NSCLC, the evolving role of individualized therapy","volume":"4","author":"Domvri","year":"2013","journal-title":"J. Cancer"},{"issue":"Suppl 4","key":"10.1016\/j.rmcr.2017.10.006_bib2","first-page":"S389","article-title":"Treatment of non-small cell lung cancer (NSCLC)","volume":"5","author":"Zarogoulidis","year":"2013","journal-title":"J. Thorac. Dis."},{"issue":"4","key":"10.1016\/j.rmcr.2017.10.006_bib3","first-page":"256","article-title":"Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy","volume":"2","author":"Domvri","year":"2013","journal-title":"Transl. Lung Cancer Res."},{"issue":"21","key":"10.1016\/j.rmcr.2017.10.006_bib4","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2017.10.006_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2017.08.005","article-title":"PD-1 checkpoint inhibition: toxicities and management","author":"Hahn","year":"2017","journal-title":"Urol. Oncol."},{"issue":"34","key":"10.1016\/j.rmcr.2017.10.006_bib6","doi-asserted-by":"crossref","first-page":"57826","DOI":"10.18632\/oncotarget.18406","article-title":"The efficacy of anti-PD-1\/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer","volume":"8","author":"Sheng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.rmcr.2017.10.006_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","author":"Planchard","year":"2017","journal-title":"Lancet. Oncol."},{"issue":"32","key":"10.1016\/j.rmcr.2017.10.006_bib8","doi-asserted-by":"crossref","first-page":"53336","DOI":"10.18632\/oncotarget.18408","article-title":"Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: data from a cohort of 713 non-squamous NSCLC lacking KRAS\/EGFR\/HER2\/BRAF\/PIK3CA\/ALK alterations","volume":"8","author":"Dugay","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.rmcr.2017.10.006_bib9","doi-asserted-by":"crossref","first-page":"11893","DOI":"10.1038\/s41598-017-12131-x","article-title":"Upregulation of CISD2 augments ROS homeostasis and contributes to tumorigenesis and poor prognosis of lung adenocarcinoma","volume":"7","author":"Li","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.rmcr.2017.10.006_bib10","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13046-017-0584-3","article-title":"(S)-crizotinib induces apoptosis in human non-small cell lung cancer cells by activating ROS independent of MTH1","volume":"36","author":"Dai","year":"2017","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"10.1016\/j.rmcr.2017.10.006_bib11","first-page":"109","article-title":"Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy","volume":"8","author":"Santarpia","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmcr.2017.10.006_bib12","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2017-0262","article-title":"Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors ceritinib","author":"De Pas","year":"2017","journal-title":"Future Oncol."},{"key":"10.1016\/j.rmcr.2017.10.006_bib13","first-page":"171","article-title":"Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series","volume":"21","author":"Zarogoulidis","year":"2017","journal-title":"Respir. Med. Case Rep."},{"issue":"1","key":"10.1016\/j.rmcr.2017.10.006_bib14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40169-017-0135-8","article-title":"Tissue is the issue and tissue competition. Re-biopsy for mutation T790: where and why?","volume":"6","author":"Zarogoulidis","year":"2017","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.rmcr.2017.10.006_bib15","first-page":"187","article-title":"Endobronchial ultrasound convex probe for lymphoma, sarcoidosis, lung cancer and other thoracic entities. A case series","volume":"22","author":"Zarogoulidis","year":"2017","journal-title":"Respir. Med. Case Rep."},{"key":"10.1016\/j.rmcr.2017.10.006_bib16","doi-asserted-by":"crossref","DOI":"10.2174\/1570159X15666170915143217","article-title":"Prevention and treatment for chemotherapy-induced peripheral neuropathy: therapies based on CIPN mechanisms","author":"Hu","year":"2017","journal-title":"Curr. Neuropharmacol."},{"issue":"10","key":"10.1016\/j.rmcr.2017.10.006_bib17","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s12032-017-1036-9","article-title":"Theoretical method for evaluation of therapeutic effects and adverse effects of epidermal growth factor receptor tyrosine kinase inhibitors in clinical treatment","volume":"34","author":"Kimura","year":"2017","journal-title":"Med. Oncol."},{"key":"10.1016\/j.rmcr.2017.10.006_bib18","first-page":"64","article-title":"\"Liquid elbows\" due to afatinib administration","volume":"22","author":"Zarogoulidis","year":"2017","journal-title":"Respir. Med. Case Rep."},{"key":"10.1016\/j.rmcr.2017.10.006_bib19","first-page":"197","article-title":"Immunotherapy \"Shock\" a case series of PD-L1 100% and pembrolizumab first-line treatment","volume":"22","author":"Zarogoulidis","year":"2017","journal-title":"Respir. Med. Case Rep."},{"key":"10.1016\/j.rmcr.2017.10.006_bib20","first-page":"101","article-title":"Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases","volume":"22","author":"Zarogoulidis","year":"2017","journal-title":"Respir. Med. Case Rep."},{"issue":"7","key":"10.1016\/j.rmcr.2017.10.006_bib21","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."}],"container-title":["Respiratory Medicine Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221300711730312X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221300711730312X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,26]],"date-time":"2018-08-26T09:25:53Z","timestamp":1535275553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221300711730312X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":21,"alternative-id":["S221300711730312X"],"URL":"https:\/\/doi.org\/10.1016\/j.rmcr.2017.10.006","relation":{},"ISSN":["2213-0071"],"issn-type":[{"type":"print","value":"2213-0071"}],"subject":[],"published":{"date-parts":[[2017]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy \u201cShock\u201d with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmcr.2017.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}